

Supporting Information

for

Competitive cyclization of ethyl trifluoroacetoacetate and methyl ketones with 1,3-diamino-2-propanol into hydrogenated oxazolo- and pyrimido-condensed pyridones

Svetlana O. Kushch, Marina V. Goryaeva, Yanina V. Burgart, Marina A. Ezhikova, Mikhail I. Kodess, Pavel A. Slepukhin, Alexandrina S. Volobueva, Vladimir V. Zarubaev and Victor I. Saloutin

Beilstein J. Org. Chem. 2025, 21, 2716-2729. doi:10.3762/bjoc.21.209

General synthetic procedures, characterization data, XRD analysis data and copies of ¹H, ¹⁹F, ¹³C NMR spectra, IR spectra, HRMS spectra of all synthesized compounds

Table of contents

Detailed experimental procedures and spectroscopic data for all synthesized	
compounds	S2
X-ray analysis	S11
Cytotoxicity and anti-viral activity evaluation	S20
References	S21
Copies of ¹ H, ¹⁹ F and ¹³ C NMR spectra	S22
Copies of IR spectra	S44
Copies of HRMS spectra	S52

Experimental

General remarks: Melting points were measured in open capillaries with a Stuart SMP3 melting-point apparatus. The IR spectra were recorded on a Perkin-Elmer Spectrum Two FT-IR spectrometer with diamond ATR accessory in the range of 400–4000 cm⁻¹. The ¹H, ¹⁹F NMR spectra were registered on a Bruker DRX-400 spectrometer (400 or 376 MHz, respectively). The ¹³C NMR spectra were recorded on a Bruker AVANCE III 500 spectrometer (126 MHz). The NMR spectra for all compounds were registered using the solvent DMSO-*d*₆. The internal standard was SiMe₄ for ¹H NMR spectra and C₆F₆ for ¹⁹F. The ¹³C chemical shifts were calibrated using the solvent signal DMSO-*d*₆ (δc 39.5 ppm). For all compounds the signals in the ¹H and ¹³C spectra were assigned based on 2D ¹H-¹H COSY, ¹H-¹H NOESY, ¹H-¹³C HSQC and HMBC experiments. High-resolution mass spectra (HRMS) were recorded on a Bruker maXis impact mass spectrometer (ESI). Column chromatography was performed on silica gel 60 (0.063–0.200 mm) (Macherey-Nagel). Ethyl 4,4,4-trifluoroacetoacetate (1), acetone (2a), 2-butanone (2b), 2-hexanone (2c), acetophenone (2d), 1,3-diaminopropan-2-ol (3) are commercially available (purchased from Alfa Aesar, Acros Organics, and Sigma-Aldrich).

General procedure for the synthesis of 4, 5

Procedure A: A 30-mL screw cap vial was charged with a mixture of ethyl trifluoroacetoacetate (**1**, 0.92 g, 5 mmol) and methyl ketone **2a–d** (5 mmol) in 1,4-dioxane (5 mL). Diaminopropanol **3** (0.45 g, 5 mmol) was then added, and the mixture was stirred at 60 °C for 24–48 h. The progress of reaction was monitored by TLC and ¹⁹F NMR. If a solid precipitated (for **4a**,**b**,**d**^{ct}), it was filtered off and recrystallized from MeCN. Product **4a**^{tt} precipitated from the cold filtrate, was filtered and recrystallized from MeCN. If no precipitate was formed (for **4a**,**b**^{tc}, **4a**–**d**^{cc}, **4c**^{ct}, **5a**–**c**^{tc}, **5a**–**c**^{tt}), the reaction mixture was concentrated on a rotary evaporator, the residue was purified by column chromatography using gradient elution [eluent AcOEt, MeCN, MeCN:EtOH (4:1, 7:3, 1:1)].

Procedure B: A 30-mL screw cap vial was charged with a mixture of ethyl trifluoroacetoacetate (1, 0.92 g, 5 mmol) and methyl ketone **2a–d** (5 mmol) in 1,4-dioxane (5 mL). Diaminopropanol **3** (0.45 g, 5 mmol), acetic acid (0.6 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) were then added, and the mixture was stirred at 60 °C for 24–48 h. The progress of reaction was monitored by TLC and ¹⁹F NMR. The products **4a–c**^{ct}, **4a**^{tt}, **4a,b**^{tc}, **4a–c**^{cc}, **5c**^{tt} obtained from reactions with methyl ketones **2a–c** were isolated similarly to the procedure A. In the case of a reaction with acetophenone **2d** the

reaction mixture was concentrated on a rotary evaporator, the residue was washed with hot MeCN and recrystallized from EtOH to give product **4d**^{cc}. The filtrates were then combined and concentrated on a rotary evaporator. The residue was purified by column chromatography using gradient elution (eluent AcOEt, MeCN) to give product **4d**^{ct}.

(3R*,8R*,9aR*)-3,8-Dihydroxy-9a-methyl-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4a**^{cc})

Yield 6% (0.085 g, A), 23% (0.31 g, B); white solid; m.p. 220–223°C (eluent MeCN). 1 H NMR δ : 1.49 (s, 3H, Me), 2.06 (dd, J = 14.1, 3.5 Hz, 1H, H-9B), 2.11 (d, J = 14.1 Hz, 1H, H-9A), 2.48 (dd, J = 16.2, 3.5 Hz, 1H, H-7B, overlapped with DMSO), 2.67–2.77 (m, 3H, H-7A, H-4A, H-2B), 2.86 (dm, J = 13.2 Hz, 1H, H-2A), 3.17 (dd, J = 10.7, 3.5 Hz, 1H, NH), 3.21 (tq, J = 10.7, 5.0 Hz, 1H, H-3), 4.55 (ddd, J = 12.6, 5.4, 1.8 Hz, 1H, H-4A), 5.08 (d, J = 5.0 Hz, 1H, HO-C³), 7.08 (s, 1H, HO-C³) ppm. 13 C NMR δ : 24.2 (Me), 37.7 (C-7), 37.9 (C-9), 42.6 (C-4), 46.8 (C-2), 64.3 (C-3), 69.3 (C-9a), 70.4 (q, J = 28.8 Hz, C-8), 125.0 (q, J = 285.2 Hz, CF₃), 163.9 (C-6) ppm. 19 F NMR δ : 79.91 (s, CF₃) ppm. IR v: 3429, 3278 (N–H, O–H), 2969–2872 (C–H), 1632 (C=O), 1452–1417 (C–N), 1170–1080 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₀H₁₆F₃N₂O₃ [M + H]+ 269.1108; found 269.1109.

(3S*,8R*,9aR*)-3,8-Dihydroxy-9a-methyl-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4a**^{ct})

Yield 4% (0.055 g, A), 8% (0.11 g, B); white solid; m.p. 215°C (from MeCN). ¹H NMR δ: 1.46 (s, 3H, Me), 2.00 (dd, J = 14.0, 3.4 Hz, 1H, H-9B), 2.06 (d, J = 14.0 Hz, 1H, H-9A), 2.53 (dd, J = 16.6, 3.4 Hz, 1H, H-7B, overlapped with DMSO), 2.59–2.64 (m, 2H, H-7A, H-2B), 3.09 (dm, J = 13.8 Hz, 1H, H-4B), 3.16 (br.d, J = 14.2 Hz, 1H, H-2A), 3.49 (br.qw, J = 2.2 Hz, 1H, H-3), 4.51 (br.s, 1H, HO-C³), 4.54 (dt, J = 13.8, 2.4 Hz, 1H, H-4A), 6.91 (br.s, 1H, HO-C³) ppm. ¹³C NMR δ: 24.2 (Me), 37.6 (C-7), 39.0 (C-9), 42.0 (C-4), 45.9 (C-2), 62.4 (C-3), 69.3 (C-9a), 70.3 (q, J = 28.6 Hz, C-8), 125.2 (q, J = 285.4 Hz, CF₃), 164.3 (C-6) ppm. ¹9F NMR δ: 80.02 (s, CF₃) ppm. IR v: 3299, 3190 (N–H, O–H), 2994–2865

(C–H), 1625 (C=O), 1475–1412 (C–N), 1188–1064 (C–F) cm^{-1} . HRMS (ESI): m/z calcd. for $C_{10}H_{16}F_3N_2O_3$ [M + H]⁺ 269.1108; found 269.1108.

(3S*,8R*,9aS*)-3,8-Dihydroxy-9a-methyl-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4a**^{tt})

Yield 26% (0.349 g, A), 20% (0.269 g, B); white solid; m.p. 205–209°C (from MeCN). 1 H NMR δ : 1.56 (s, 3H, Me), 1.98 (AB-system, Δ_{AB} = 0.02, $^2J_{AB}$ = 14.0 Hz, $^4J_{9A,7B}$ = 2.6 Hz, 2H, H-9), 2.43 (dd, J = 16.8, 2.6 Hz, 1H, H-7B), 2.55 (dm, J = 14.4 Hz, 1H, H-2B), 2.58 (d, J = 16.8 Hz, 1H, H-7A), 2.59 (br.d, J = 13.7 Hz, 1H, NH), 2.96 (dd, J = 14.0, 2.0 Hz, 1H, H-4B), 3.13 (ddd, J = 14.3, 12.3, 2.2 Hz, 1H, H-2A), 3.53 (dqw, J = 6.4, 2.2 Hz, 1H, H-3), 4.42 (dt, J = 14.0, 2.4 Hz, 1H, H-4A), 4.70 (d, J = 6.4 Hz, 1H, HO-C³), 6.34 (s, 1H, HO-C³) ppm. 13 C NMR δ : 22.4 (Me), 37.1 (C-7), 39.1 (C-9), 41.6 (C-4), 44.2 (C-2), 62.8 (C-3), 69.4 (C-9a), 70.2 (q, J = 28.1 Hz, C-8), 125.5 (q, J = 286.5 Hz, CF₃), 164.0 (C-6) ppm. 19 F NMR δ : 79.52 (s, CF₃) ppm. IR v: 3332, 3287 (N–H, O–H), 3023–2883 (C–H), 1593 (C=O), 1461–1411 (C–N), 1168–1080 (C–F) cm-1. HRMS (ESI): m/z calcd. for C₁₀H₁₆F₃N₂O₃ [M + H]+ 269.1108; found 269.1110.

(3R*,8R*,9aS*)-3,8-Dihydroxy-9a-methyl-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4a**^{tc})

Yield 15% (0.202 g, A), 13% (0.175 g, B); white solid; m.p. 189–190°C (eluent MeCN). ¹H NMR δ : 1.55 (s, 3H, Me), 1.87 (d, J = 13.8 Hz, 1H, H-9B), 2.05 (dd, J = 13.8, 3.2 Hz, 1H, H-9A), 2.44 (dd, J = 16.9, 3.2 Hz, 1H, H-7B), 2.49–2.55 (m, 2H, H-7A, H-4B, overlapped with DMSO), 2.62–2.77 (m, 3H, H-2, NH), 3.28 (tqw, J = 10.4, 5.0 Hz, 1H, H-3), 4.54 (ddd, J = 12.8, 5.4, 1.7 Hz, 1H, H-4A), 5.03 (d, J = 5.0 Hz, 1H, HO-C³), 6.35 (s, 1H, HO-C8) ppm. ¹³C NMR δ : 22.7 (Me), 36.9 (C-7), 38.9 (C-9), 42.0 (C-4), 45.4 (C-2), 64.8 (C-3), 68.9 (C-9a), 70.2 (q, J = 28.0 Hz, C-8), 125.5 (q, J = 286.4 Hz, CF₃), 163.0 (C-6) ppm. ¹⁹F NMR δ : 79.61 (s, CF₃) ppm. IR v: 3315, 3286 (N–H, O–H), 3003–2906 (C–H), 1623 (C=O), 1466–1412 (C–N), 1172–1069 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₀H₁₆F₃N₂O₃ [M + H]⁺ 269.1108; found 269.1109.

(3S*,8R*,9aR*)-9a-Ethyl-3,8-dihydroxy-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4b**^{ct})

Yield 13% (0.184 g, A), 22% (0.315 g, B); white solid; m.p. 231–234°C (from MeCN). ¹H NMR δ: 0.75 (t, J = 7.3 Hz, 3H, H-2'), 1.75 (dq, J = 14.6, 7.3 Hz, 1H, H-1'B), 1.85 (dd, J = 14.2, 3.2 Hz, 1H, H-9B), 1.94 (dq, J = 14.6, 7.3 Hz, 1H, H-1'A), 1.96 (d, J = 14.2 Hz, 1H, H-9A), 2.44–2.51 (br.s, 1H, NH, overlapped with DMSO), 2.53 (dd, J = 16.5, 3.4 Hz, 1H, H-7B), 2.57 (d, J = 16.5 Hz, 1H, H-7A), 2.59 (dt, J = 14.4, 2.0 Hz, 1H, H-2B), 2.94 (dd, J = 14.0, 1.7 Hz, 1H, H-4B), 3.12 (br.d, J = 14.0 Hz, 1H, H-2A), 3.48 (m, 1H, H-3), 4.53 (dt, J = 14.0, 2.3 Hz, 1H, H-4A), 4.55 (br.s, 1H, OH-C³), 6.89 (br.s, 1H, OH-C³) ppm. ¹³C NMR δ: 7.6 (C-2'), 26.6 (C-1'¹), 35.8 (C-9), 37.4 (C-7), 41.7 (C-4), 45.4 (C-2), 62.1 (C-3), 70.3 (q, J = 28.5 Hz, C-8), 71.8 (C-9a), 125.3 (q, J = 285.7 Hz, CF₃), 164.8 (C-6) ppm. ¹⁹F NMR δ: 80.09 (s, CF₃) ppm. IR v: 3298, 3208 (N–H, O–H), 2970–2916 (C–H), 1627 (C=O), 1476–1413 (C–N), 1183–1079 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₁H₁₈F₃N₂O₃ [M + H]⁺ 283.1264; found 283.1266.

(3R*,8R*,9aR*)-9a-Ethyl-3,8-dihydroxy-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (mixture of diastereomers **4b**^{cc}: **4b**^{tc} in the ratio 4:1)

4bcc: 4btc in the ratio 4:1

Yield 21% (0.298 g, A), 32% (0.452 g, B); white solid; m.p. 219–222°C (eluent AcOEt). 1 H NMR δ : 0.75 (t, J = 7.3 Hz, 2.4H, H-2' **4b**^{cc}), 0.81 (t, J = 7.3 Hz, 0.6H, H-2' **4b**^{tc}), 1.54 (d, J = 14.3 Hz, 0.2H, H-9B **4b**^{tc}), 1.70 (dq, J = 14.6, 7.3 Hz, 0.8H, H-1'B **4b**^{cc}), 1.83–1.91 (m, 0.2H, H-1'B **4b**^{tc}), 1.89 (dd, J = 14.2, 3.6 Hz, 0.8H, H-9B **4b**^{cc}), 2.01 (d, 0.8H, J = 14.2 Hz, H-9A **4b**^{cc}), 2.04 (dq, J = 14.6, 7.3 Hz, 0.8H, H-1'A **4b**^{cc}), 2.17 (dd, J = 14.3, 2.9 Hz, 0.2H, H-9A **4b**^{tc}), 2.24 (dq, J = 14.5, 7.3 Hz, 0.2H, H-1'A **4b**^{tc}), 2.45–2.61 (m, 2.6H, H-4B, H-7B **4b**^{cc}, H-2B **4b**^{tc}, NH **4b**^{tc}, part. overlapped with DMSO), 2.65 (d, J = 16.1, 0.8H, H-7A **4b**^{cc}), 2.68–2.73 (m, 1H, H-2B **4b**^{cc}, H-2A **4b**^{tc}), 2.85 (br.d, J = 13.0 Hz, 0.8H, H-2A **4b**^{cc}), 3.11 (m, 0.8H, NH **4b**^{cc}), 3.21 (tq, J = 10.6, 5.1 Hz, 0.8H, H-3 **4b**^{cc}), 3.27–3.34 (m, 0.2H, H-3 **4b**^{tc}, part. overlapped with H₂O), 4.52–4.56 (m, 0.2H, H-4A **4b**^{tc}), 4.56 (ddd, J = 12.6, 5.2, 1.4 Hz, 0.8H, H-4A **4b**^{cc}), 5.00 (d, J = 4.9 Hz, 0.2H, HO-C³ **4b**^{tc}), 5.06

(d, J = 5.1 Hz, 0.8H, HO-C³ **4b**^{cc}), 6.30 (s, 0.2H, HO-C⁸ **4b**^{tc}), 7.04 (s, 0.8H, HO-C⁸ **4b**^{cc}). ¹³C NMR δ : 7.4 (C-2', **4b**^{cc}), 8.4 (C-2', **4b**^{tc}), 23.6 (C-1', **4b**^{tc}), 26.6 (C-1', **4b**^{tc}), 33.1 (C-9, **4b**^{tc}), 34.7 (C-9, **4b**^{cc}), 37.1 (C-7, **4b**^{tc}), 37.5 (C-7, **4b**^{cc}), 41.9 (C-4, **4b**^{tc}), 42.3 (C-4, **4b**^{cc}), 45.0 (C-2, **4b**^{tc}), 46.4 (C-2, **4b**^{cc}), 63.8 (C-3, **4b**^{cc}), 64.4 (C-3, **4b**^{tc}), 70.1 (q, J = 28.1 Hz, C-8, **4b**^{tc}), 70.4 (q, J = 28.8 Hz, C-8, **4b**^{cc}), 71.6 (C-9a, **4b**^{tc}), 71.8 (C-9a, **4b**^{cc}), 125.1 (q, J = 285.3 Hz, CF₃, **4b**^{cc}), 125.6 (q, J = 286.4 Hz, CF₃, **4b**^{tc}), 163.5 (C-6, **4b**^{tc}), 164.3 (C-6, **4b**^{cc}) ppm. ¹⁹F NMR δ : 79.50 (s, 0.6F, CF₃, **4b**^{tc}), 80.00 (s, 2.4F, CF₃, **4b**^{cc}) ppm. IR v: 3435, 3278 (N-H, O-H), 2981–2894 (C-H), 1633 (C=O), 1450–1416 (C-N), 1180–1095 (C-F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₁H₁₈F₃N₂O₃ [M + H]⁺ 283.1264; found 283.1267.

(3R*,8R*,9aR*)-9a-Butyl-3,8-dihydroxy-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4c**^{cc})

Yield 8% (0.125 g, A), 21% (0.326 g, B); white solid; m.p. 184–186°C (eluent AcOEt). 1 H NMR δ: 0.89 (t, J = 7.2 Hz, 3H, H-4'), 0.96–1.05 (m, 1H, H-2'B), 1.19–1.27 (m, 1H, H-2'A), 1.31 (sex, J = 7.2 Hz, 2H, H-3'), 1.66 (ddd, J = 14.0, 12.3, 3.8 Hz, 1H, H-1'B), 1.92 (dd, J = 14.1, 3.5 Hz, 1H, H-9B), 2.01 (ddd, J = 14.0, 11.9, 4.9 Hz, 1H, H-1'A), 2.04 (d, J = 14.1 Hz, 1H, H-9A), 2.48 (dd, J = 16.1, 3.5 Hz, 1H, H-7B), 2.54 (dd, J = 12.6, 11.0 Hz, 1H, H-4B), 2.65 (d, J = 16.1 Hz, 1H, H-7A), 2.71 (dt, J = 13.1, 10.8 Hz 1H, H-2B), 2.85 (dm, J = 13.1 Hz, 1H, H-2A), 3.11 (dd, J = 10.8, 3.6 Hz, 1H, NH), 3.21 (tq, J = 10.8, 5.1 Hz, 1H, H-3), 4.56 (ddd, J = 12.6, 5.3, 1.5 Hz, 1H, H-4A), 5.06 (d, J = 5.1 Hz, 1H, HO-C³), 7.04 (s, 1H, HO-C³) ppm. 13 C NMR δ: 13.9 (C-4'), 22.1 (C-3'), 24.9 (C-2'), 33.7 (C-1'), 35.2 (C-9), 37.5 (C-7), 42.4 (C-4), 46.4 (C-2), 63.8 (C-3), 70.4 (q, J = 28.8 Hz, C-8), 71.4 (C-9a), 125.0 (q, J = 285.3 Hz, CF₃), 164.2 (C-6) ppm. 19 F NMR δ: 80.00 (s, CF₃) ppm. IR v: 3309, 3267, 3189 (N-H, O-H), 2964–2873 (C-H), 1626 (C=O), 1475–1412 (C-N), 1171–1084 (C-F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₃H₂₂F₃N₂O₃ [M + H]⁺ 311.1577; found 311.1578.

(3S*,8R*,9aR*)-9a-Butyl-3,8-dihydroxy-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4c**^{ct})

Yield 13% (0.202 g, A), 18% (0.28 g, B); white solid; m.p. 174–177°C (eluent MeCN). 1 H NMR δ : 0.88 (t, J = 7.2 Hz, 3H, H-4'), 0.96–1.05 (m, 1H, H-2'B), 1.19–1.27 (m, 2H, H-2'A), 1.31 (sex, J = 7.2 Hz, 2H, H-3'), 1.71 (ddd, J = 13.9, 12.3, 3.9 Hz, 1H, H-1'B), 1.87 (dd, J = 14.1, 3.3 Hz, 1H, H-9B), 1.90 (ddd, J = 13.9, 11.8, 4.7 Hz, 1H, H-1'A), 2.00 (d, J = 14.1 Hz, 1H, H-9A), 2.52 (dd, J = 16.3, 3.3 Hz, 1H, H-7B, overlapped with DMSO), 2.57 (d, J = 16.3 Hz, 1H, H-7A), 2.59 (dq, J = 14.1, 2.5 Hz, 1H, H-2B), 2.96 (dd, J = 13.9, 1.4 Hz, 1H, H-4B), 3.13 (ddd, J = 14.1, 12.0, 2.1 Hz, 1H, H-2A), 3.25 (dd, J = 11.9, 3.2 Hz, 1H, NH), 3.49 (br.sex, J = 2.5 Hz, 1H, H-3), 4.51 (d, J = 2.5 Hz, 1H, HO-C³), 4.54 (dt, J = 13.9, 2.4 Hz, 1H, H-4A), 6.90 (s, 1H, HO-C³) ppm. 13 C NMR δ : 14.0 (C-4'), 22.2 (C-3'), 25.2 (C-2'), 33.8 (C-1'), 36.4 (C-9), 37.5 (C-7), 41.8 (C-4), 45.4 (C-2), 62.1 (C-3), 70.3 (q, J = 28.3 Hz, C-8), 71.5 (C-9a), 125.3 (q, J = 285.6 Hz, CF₃), 164.7 (C-6) ppm. 19 F NMR δ : 80.09 (s, CF₃) ppm. IR v: 3302, 3126 (N–H, O–H), 2938–2852 (C–H), 1629 (C=O), 1485–1423 (C–N), 1192–1079 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₃H₂₂F₃N₂O₃ [M + H]⁺ 311.1577; found 311.1579.

(3R*,8R*,9aR*)-3,8-Dihydroxy-9a-phenyl-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4d**^{cc})

Yield 5% (0.083 g, A), 54% (0.892 g, B); white solid; m.p. 253–255°C (eluent AcOEt (A); from EtOH (B)). 1 H NMR δ : 1.91 (d, J = 14.2 Hz, 1H, H-9B), 2.16 (dd, J = 14.2, 3.6 Hz, 1H, H-9A), 2.25 (dt, J = 12.4, 11.0 Hz, 1H, H-4B), 2.38 (dt, J = 12.8, 11.0 Hz, 1H, H-2B), 2.63 (dd, J = 16.1, 3.6 Hz, 1H, H-7B), 2.93 (d, J = 12.8 Hz, 1H, H-2A), 2.97 (d, J = 16.1 Hz, 1H, H-7A), 3.32 (tq, J = 10.4, 5.1 Hz, 1H, H-3, overlapped with H₂O), 3.71 (dd, J = 11.7, 3.8 Hz, 1H, NH), 4.55 (ddd, J = 12.4, 5.1, 2.0 Hz, 1H, H-4A), 4.96 (d, J = 5.1 Hz, 1H, HO-C³), 7.20 (s, 1H, HO-C³), 7.33 (tt, J = 7.2, 1.5 Hz, 1H, H ρ), 7.42–7.50 (m, 4H, H ρ , H ρ) ppm. 13 C NMR δ : 37.6 (C-6), 41.2 (C-9), 44.4 (C-4), 47.6 (C-2), 63.9 (C-3), 70.9 (q, J = 29.0 Hz, C-8), 75.2 (C-9a), 124.8 (q, J = 285.5 Hz, CF₃), 126.2 (C ρ), 127.5 (C ρ), 129.1 (C ρ), 142.7 (C ρ), 165.2 (C-6) ppm. 19 F NMR δ : 79.94 (s, CF₃) ppm. IR v: 3335, 3280 (N–

H, O–H), 2950 (C–H), 1612 (C=O), 1462–1414 (C–N), 1170–1119 (C–F) cm^{-1} . HRMS (ESI): m/z calcd. for C₁₅H₁₈F₃N₂O₃ [M + H]⁺ 331.1264; found 331.1266.

(3S*,8R*,9aR*)-3,8-Dihydroxy-9a-phenyl-8-(trifluoromethyl)octahydro-6H-pyrido[1,2-a]pyrimidin-6-one (**4d**^{ct})

Yield 59% (0.975 g, A), 6% (0.102 g, B); white solid; m.p. 244–246°C (from MeCN (A), eluent MeCN (B)). 1 H NMR δ : 1.83 (d, J = 14.1 Hz, 1H, H-9B), 2.12 (dd, J = 14.1, 3.6 Hz, 1H, H-9A), 2.64 (dd, J = 13.5, 1.6 Hz, 1H, H-4B), 2.66–2.71 (m, 2H, H-7B, H-2B), 2.75 (ddd, J = 14.2, 12.0, 1.9 Hz, 1H, H-2A), 2.85 (d, J = 16.5 Hz, 1H, H-7A), 3.35 (m, 1H, H-3, part. overlapped with H₂O), 3.91 (dd, J = 12.0, 3.6 Hz, 1H, NH), 4.62 (dt, J = 13.5, 2.4 Hz, 1H, H-4A), 4.70 (br.d, J = 2.8 Hz, 1H, HO-C³), 7.11 (s, 1H, HO-C⁸), 7.32 (tt, J = 7.1, 1.6 Hz, 1H, Hp), 7.41–7.47 (m, 4H, Ho, Hm) ppm. 13 C NMR δ : 37.6 (C-7), 42.3 (C-9), 43.6 (C-4), 46.7 (C-2), 62.1 (C-3), 70.7 (q, J = 28.6 Hz, C-8), 75.2 (C-9a), 125.0 (q, J = 286.0 Hz, CF₃), 126.1 (Co), 127.4 (Cp), 128.9 (Cm), 142.9 (Ci), 165.8 (C-6) ppm. 19 F NMR δ : 80.03 (s, CF₃) ppm. IR v: 3332, 3136 (N–H, O–H), 2964–2933 (C–H), 1630 (C=O), 1471–1411 (C–N), 1162–1080 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₅H₁₈F₃N₂O₃ [M + H]⁺ 331.1264; found 331.1265.

2-(Aminomethyl)-7-hydroxy-8a-methyl-7-(trifluoromethyl)hexahydro-5H-oxazolo[3,2-a]pyridin-5-one (mixture of diastereomers **5a**^{tc}: **5a**^{tt} in the ratio 11:9)

$$F_3C$$
 HO
 Me
 NH_2
 HO
 Me
 NH_2
 HO
 Me
 NH_2
 HO
 Me

5atc: 5att in the ratio 11:9

Yield 14% (0.188 g, A); white solid; m.p. 155–157°C (eluent MeCN : EtOH (1:1)). ¹H NMR δ : 1.30–1.49 (br.s, 2H, NH₂), 1.51 (s, 3H, Me), 1.87 (br.d, J = 13.4 Hz, 1H, H-8B), 2.24 (d, J = 13.5 Hz, 0.55H, H-8A δ a^{tc}), 2.32 (d, J = 13.5 Hz, 0.45H, H-8A δ a^{tt}), 2.53–2.65 (m, 2.9H, H-1' δ a^{tt}), H-6), 2.71 (ABX system, Δ AB = 0.03 ppm, JAB = 13.1, JBX = 5.6, JAX = 5.1 Hz, 1.1H, H-1' δ a^{tc}), 3.08 (dd, J = 11.3, 9.4 Hz, 0.55H, H-3B δ a^{tc}), 3.40 (dd, J = 11.3, 7.6 Hz, 0.45H, H-3B δ a^{tt}), 3.70 (dd, J = 11.3, 6.0 Hz, 0.45H, H-3A δ a^{tt}), 3.84 dq, 0.55H, H-2 δ a^{tc}), 4.17–4.23 (m, 1H, H-3A δ a^{tc}, H-2 δ a^{tt}), 6.52 (s, 1H, OH). ¹³C NMR δ : 25.0 (Me, δ a^{tt}), 27.6 (Me, δ a^{tc}), 37.2 (C-6, δ a^{tt}), 37.5 (C-6, δ a^{tc}), 38.8 (C-8, δ a^{tt}), 39.6 (C-8, δ a^{tc}),

44.2 (C-1', **5a**^{tc}), 44.3 (C-3, **5a**^{tt}), 44.5 (C-1', **5a**^{tt}), 44.7 (C-3, **5a**^{tc}), 69.9 (q, J = 28.6 Hz, C-7, **5a**^{tc}), 70.6 (q, J = 28.6 Hz, C-7, **5a**^{tt}), 75.3 (C-2, **5a**^{tt}), 76.8 (C-2, **5a**^{tc}), 91.1 (C-8a, **5a**^{tc}), 91.3 (C-8a, **5a**^{tt}), 125.6 (q, J = 286.0 Hz, CF₃, **5a**^{tt}), 125.8 (q, J = 286.0 Hz, CF₃, **5a**^{tc}), 163.2 (C-5, **5a**^{tt}), 163.3 (C-5, **5a**^{tc}) ppm. ¹⁹F NMR δ: 79.66 (s, 1.7F, CF₃, **5a**^{tc}), 79.74 (s, 1.3F, CF₃, **5a**^{tt}) ppm. IR v: 3352, 3296 (NH₂), 2614 (O-H), 2985–2862 (C-H), 1628 (C=O), 1471–1444 (C-N), 1184–1125 (C-F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₀H₁₆F₃N₂O₃ [M + H]⁺ 269.1108; found 269.1107.

 $(2R^*,7R^*,8aR^*)$ -2-(Aminomethyl)-8a-ethyl-7-hydroxy-7-(trifluoromethyl)hexahydro-5H-oxazolo[3,2-a]pyridin-5-one $(\mathbf{5b^{tc}})$

Yield 16% (0.228 g, A); white solid; m.p. 158–160°C (eluent MeCN : EtOH (4:1)). ¹H NMR δ : 0.88 (t, J = 7.4 Hz, 3H, H-2"), 1.43 (br.s, 2H, NH₂), 1.78 (d, J = 14.1 Hz, 1H, H-8B), 1.82 (q, J = 7.4 Hz, 2H, H-1"), 2.28 (d, J = 14.1 Hz, 1H, H-8A), 2.61 (AB-system, Δ_{AB} = 0.02 ppm, J_{AB} = 17.3 Hz, 2H, H-6), 2.69 (dd, J = 13.1, 5.6 Hz, 1H, H-1'B), 2.74 (dd, J = 13.1, 5.3 Hz, 1H, H-1'A), 2.98 (dd, J = 11.2, 9.7 Hz, 1H, H-3B), 3.84 (dq, J = 9.7, 5.6 Hz, 1H, H-2), 4.13 (dd, J = 11.2, 5.9 Hz, 1H, H-3A), 6.53 (s, 1H, OH) ppm. ¹³C NMR δ : 7.6 (C-2"), 31.2 (C-1"), 38.07 and 38.09 (C-6 and C-8), 43.7 (C-1'), 45.9 (C-3), 69.8 (q, J = 28.6 Hz, C-7), 76.4 (C-2), 93.5 (C-8a), 126.0 (q, J = 286.1 Hz, CF₃), 163.9 (C-5) ppm. ¹⁹F NMR δ : 79.65 (s, CF₃) ppm. IR v: 3354, 3296 (NH₂), 2976–2877 (C–H), 2583 (O–H), 1656 (C=O), 1432–1420 (C–N), 1185–1105 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₁H₁₈F₃N₂O₃ [M + H]⁺ 283.1264; found 283.1266.

 $(2S^*,7R^*,8aR^*)$ -2-(Aminomethyl)-8a-ethyl-7-hydroxy-7-(trifluoromethyl)hexahydro-5H-oxazolo[3,2-a]pyridin-5-one $(\mathbf{5b^{tt}})$

Yield 18% (0.255 g, A); white solid; m.p. 158–160°C (eluent MeCN : EtOH (4:1)). ¹H NMR δ : 0.88 (t, J = 7.2 Hz, 3H, H-2"), 1.59 (br.s, 2H, NH₂), 1.67 (d, J = 13.7 Hz, 1H, H-8B), 1.77–1.91 (m, 2H, H-1"), 2.41 (d, J = 13.7 Hz, 1H, H-8A), 2.55–2.63 (m, 4H, H-1', H-6), 3.40 (dd, J = 11.3, 7.4 Hz, 1H, H-3B), 3.67 (dd, J = 11.3, 6.1 Hz, 1H, H-3A), 4.14 (dq, J = 7.4, 5.6 Hz, 1H, H-2), 6.49 (s, 1H, OH) ppm. ¹³C NMR δ : 8.1 (C-2"), 28.7 (C-1"), 35.6 (C-

8), 37.6 (C-6), 44.5 (C-1'), 44.9 (C-3), 70.6 (q, J = 28.5 Hz, C-7), 75.6 (C-2), 93.6 (C-8a), 125.8 (q, J = 286.1 Hz, CF₃), 163.4 (C-5) ppm. ¹⁹F NMR δ : 79.73 (s, CF₃) ppm. IR v: 3373, 3303 (NH₂), 2978–2865 (C-H), 2590 (O-H), 1658 (C=O), 1449–1416 (C-N), 1192–1131 (C-F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₁H₁₈F₃N₂O₃ [M + H]⁺ 283.1264; found 283.1266.

 $(2S^*,7R^*,8aR^*)$ -2-(Aminomethyl)-8a-butyl-7-hydroxy-7-(trifluoromethyl)hexahydro-5H-oxazolo[3,2-a]pyridin-5-one $(\mathbf{5c^{tc}})$

Yield 17% (0.264 g, A); white solid; m.p. 107–110°C (eluent MeCN). ¹H NMR δ: 0.88 (t, J = 7.1 Hz, 3H, H-4"), 1.22–1.32 (m, 3H, H-2"B, H-3"), 1.34–1.49 (m, 3H, H-2"A, NH₂), 1.74–1.85 (m, 3H, H-1", H-8B), 2.27 (d, J = 14.0 Hz, 1H, H-8A), 2.59 (d, J =17.1 Hz, 1H, H-6B), 2.63 (d, J = 17.1 Hz, 1H, H-6A), 2.69 (dd, J = 13.1, 5.6 Hz, 1H, H-1'B), 2.74 (dd, J = 13.1, 5.2 Hz, 1H, H-1'A), 2.98 (dd, J = 11.2, 9.7 Hz, 1H, H-3B), 3.84 (dq, J = 9.7, 5.5 Hz, 1H, H-2), 4.12 (dd, J = 11.2, 6.0 Hz, 1H, H-3A), 6.52 (s, 1H, OH) ppm. ¹³C NMR δ: 13.8 (C-4"), 22.1 (C-3"), 25.0 (C-2"), 38.0 (C-1"), 38.1 (C-6), 38.5 (C-8), 43.7 (C-1'), 45.9 (C-3), 69.8 (q, J = 28.5 Hz, C-7), 76.4 (C-2), 93.3 (C-8a), 126.0 (q, J = 285.9 Hz, CF₃), 163.9 (C-5) ppm. ¹⁹F NMR δ: 79.65 (s, CF₃) ppm. IR v: 3376, 3272, (NH₂), 2989–2868 (C–H), 2601 (O–H), 1652 (C=O), 1466–1398 (C–N), 1159–1124 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₃H₂₂F₃N₂O₃ [M + H]+ 311.1577; found 311.1575.

 $(2R^*,7R^*,8aR^*)$ -2-(Aminomethyl)-8a-butyl-7-hydroxy-7-(trifluoromethyl)hexahydro-5H-oxazolo[3,2-a]pyridin-5-one ($5c^{tt}$)

Yield 19% (0.295 g, A), 3% (0.047 g, B); white solid; m.p. 159–162°C (eluent MeCN : EtOH (7:3)). 1 H NMR δ: 0.88 (t, J = 7.1 Hz, 3H, H-4"), 1.23–1.39 (m, 4H, H-2", H-3"), 1.42 (br.s, 2H, NH₂), 1.68 (d, J = 13.6, 1.0 Hz, 1H, H-8B), 1.73–1.78 (m, 1H, H-1"B), 1.85–1.91 (m, 1H, H-1"A), 2.41 (d, J = 13.6 Hz, 1H, H-8A), 2.55–2.63 (m, 4H, H-1', H-6), 3.41 (dd, J = 11.3, 7.4 Hz, 1H, H-3B), 3.66 (dd, J = 11.3, 6.1 Hz, 1H, H-3A), 4.14 (dq, J = 7.4, 5.5 Hz, 1H, H-2), 6.49 (s, 1H, OH) ppm. 13 C NMR δ: 13.8 (C-4"), 22.1 (C-3"), 25.5 (C-2"), 35.7 (C-1"), 36.3 (C-8), 37.6 (C-6), 44.5 (C-1'), 44.9 (C-3), 70.6 (q, J = 28.7 Hz, C-7), 75.6

(C-2), 93.3 (C-8a), 125.8 (q, J = 286.1 Hz, CF₃), 163.4 (C-5) ppm. ¹⁹F NMR δ : 79.74 (s, CF₃) ppm. IR v: 3371, 3304 (NH₂), 2960–2871 (C–H), 2602 (O–H), 1652 (C=O), 1454–1423 (C–N), 1218–1136 (C–F) cm⁻¹. HRMS (ESI): m/z calcd. for C₁₃H₂₂F₃N₂O₃ [M + H]⁺ 311.1577; found 311.1575.

X-ray analysis

The XRD analyses for compounds $4a^{cc}$, $4a^{ct}$, $4a^{tt}$, $4a^{tc}$, $5c^{tc}$ and $5c^{tt}$ were carried out using equipment of the Center for Joint Use "Spectroscopy and Analysis of Organic Compounds" at the Postovsky Institute of Organic Synthesis of the Russian Academy of Sciences (Ural Branch). The experiment was accomplished on the automated X-ray diffractometer «Xcalibur 3» with CCD detector on standard procedure (MoK α -irradiation, graphite monochromator, ω -scans with 1° step at T=295(2) K). Empirical absorption correction was applied. The solution and refinement of the structures were accomplished with using Olex2 program package [1]. The structures were solved by the method of the intrinsic phases in the ShelXT program and refined by ShelXL by full-matrix least-squares method for non-hydrogen atoms [2,3]. The H-atoms at C–H bonds were placed in the calculated positions, H-atoms of the O–H and N–H bonds were solved by direct methods and were refined independently in isotropic approximation.

The atomic coordinates and other structural parameters for compounds **4a**^{cc}, **4a**^{ct}, **4a**^{tt}, **4a**^{tc}, **4d**^{ct}, **5c**^{tc} and **5c**^{tt} were deposited with the Cambridge Crystallographic Data Centre (CCDC 2479553 (**4a**^{cc}), CCDC 2479554 (**4a**^{ct}), CCDC 2479555 (**4a**^{tt}), CCDC 2479556 (**4a**^{tc}), CCDC 2479557 (**4d**^{ct}), CCDC 2479558 (**5c**^{tc}), CCDC 2479559 (**5c**^{tt})).




Figure S1: ORTEP view of compound **4a**^{cc} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479553).

,			
Table S1: Crystal data and structure refinement for 4acc			
C ₁₀ H ₁₅ F ₃ N ₂ O ₃			
268.24			
295(2)			
monoclinic			
P2 ₁ /c			
13.4535(4)			
9.4450(3)			
9.2482(3)			
90			
100.968(3)			
90			
1153.69(6)			
4			
1.544			
0.144			
560.0			
0.46 × 0.34 × 0.19			
MoKα (λ = 0.71073)			
5.302 to 62.064			
$-19 \le h \le 16, -12 \le k \le 11, -12 \le l \le 8$			
5454			
3175 [R _{int} = 0.0139, R _{sigma} = 0.0284]			
3175/0/180			
1.029			
$R_1 = 0.0402$, $wR_2 = 0.1002$			
$R_1 = 0.0581$, $wR_2 = 0.1120$			
0.20/-0.21			




Figure S2: ORTEP view of compound **4a**^{ct} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479554).

Table S2: Crystal data and structure refinement for 4act			
C ₁₀ H ₁₅ F ₃ N ₂ O ₃			
268.24			
295(2)			
orthorhombic			
Pca2 ₁			
10.4313(6)			
12.3501(15)			
8.8705(7)			
90.00			
90.00			
90.00			
1142.77(17)			
4			
1.559			
0.145			
560.0			
0.46 × 0.19 × 0.04			
5.12 to 56.56°			
$-8 \le h \le 13$, $-11 \le k \le 16$, $-11 \le l \le 11$			
4291			
$2662[R_{int} = 0.0370]$			
2662/1/176			
1.018			
$R_1 = 0.0569$, $wR_2 = 0.1060$			
$R_1 = 0.1182$, $wR_2 = 0.1369$			
0.22/-0.25			
-1.1(14)			




Figure S3: ORTEP view of compound **4a**^{tt} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479555).

Table S3: Crystal data and structure refinement for 4a ^{tt}			
Empirical formula	C ₁₀ H ₁₅ F ₃ N ₂ O ₃		
Formula weight	268.24		
Temperature/K	295(2)		
Crystal system	orthorhombic		
Space group	Pbca		
a/Å	12.5557(4)		
b/Å	10.2140(5)		
c/Å	17.9251(8)		
α/°	90		
β/°	90		
γ/°	90		
Volume/Å ³	2298.78(17)		
Z	8		
ρ _{calc} g/cm ³	1.550		
μ/mm ⁻¹	0.145		
F(000)	1120.0		
Crystal size/mm³	0.47 × 0.18 × 0.07		
Radiation	MoKα (λ = 0.71073)		
2Θ range for data collection/°	4.544 to 61.116		
Index ranges	$-8 \le h \le 17, -8 \le k \le 14, -23 \le l \le 20$		
Reflections collected	6748		
Independent reflections	3072 [Rint = 0.0332, Rsigma = 0.0518]		
Data/restraints/parameters	3072/0/180		
Goodness-of-fit on F ²	0.939		
Final R indexes [I>=2σ (I)]	$R_1 = 0.0498$, $wR_2 = 0.1239$		
Final R indexes [all data]	$R_1 = 0.0990$, $wR_2 = 0.1580$		
Largest diff. peak/hole / e Å-3	0.24/-0.18		




Figure S4: ORTEP view of compound **4a**^{tc} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479556).

Table S4: Crystal data and structure refinement for 4atc			
Empirical formula	C ₁₀ H ₁₅ F ₃ N ₂ O ₃		
Formula weight	268.24		
Temperature/K	295(2)		
Crystal system	monoclinic		
Space group	P2 ₁ /c		
a/Å	10.2698(4)		
b/Å	9.1246(3)		
c/Å	12.2297(5)		
α/°	90		
β/°	96.719(4)		
γ/°	90		
Volume/Å ³	1138.15(7)		
Z	4		
ρ _{calc} g/cm ³	1.565		
μ/mm ⁻¹	0.146		
F(000)	560.0		
Crystal size/mm³	0.49 × 0.37 × 0.28		
Radiation	ΜοΚα (λ = 0.71073)		
2Θ range for data collection/°	5.584 to 61.56		
Index ranges	$-13 \le h \le 13$, $-12 \le k \le 7$, $-17 \le l \le 10$		
Reflections collected	5278		
Independent reflections	3090 [R _{int} = 0.0167, R _{sigma} = 0.0339]		
Data/restraints/parameters	3090/0/180		
Goodness-of-fit on F ²	1.012		
Final R indexes [I>=2σ (I)]	$R_1 = 0.0456$, $wR_2 = 0.1079$		
Final R indexes [all data]	$R_1 = 0.0718$, $wR_2 = 0.1259$		
Largest diff. peak/hole / e Å ⁻³	0.22/-0.22		




Figure S5: ORTEP view of compound **4d**^{ct} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479557).

	,
Table S5: Crystal data and s	tructure refinement for 4d ^{ct}
Empirical formula	C ₁₅ H ₁₇ F ₃ N ₂ O ₃
Formula weight	330.30
Temperature/K	295(2)
Crystal system	monoclinic
Space group	Pc
a/Å	14.5622(6)
b/Å	8.7117(3)
c/Å	12.0539(5)
α/°	90
β/°	102.816(4)
γ/°	90
Volume/Å ³	1491.08(10)
Z	4
$\rho_{calc}g/cm^3$	1.471
μ/mm ⁻¹	0.127
F(000)	688.0
Crystal size/mm ³	0.47 × 0.26 × 0.15
Radiation	ΜοΚα (λ = 0.71073)
2Θ range for data collection/°	4.676 to 59.122
Index ranges	$-13 \le h \le 19$, $-12 \le k \le 5$, $-15 \le l \le 16$
Reflections collected	6483
Independent reflections	4841 [R _{int} = 0.0261, R _{sigma} = 0.0555]
Data/restraints/parameters	4841/2/448
Goodness-of-fit on F ²	1.007
Final R indexes [I>=2σ (I)]	$R_1 = 0.0449$, $wR_2 = 0.0788$
Final R indexes [all data]	$R_1 = 0.0811$, $wR_2 = 0.0967$
Largest diff. peak/hole / e Å-3	0.19/-0.19
Flack parameter	-0.8(7)




Figure S6: ORTEP view of compound **5c**^{tc} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479558).

Table S6: Crystal data and structure refinement for 5atc			
Empirical formula	C ₁₃ H ₂₁ F ₃ N ₂ O ₃		
Formula weight	310.32		
Temperature/K	295(2)		
Crystal system	monoclinic		
Space group	P2 ₁ /c		
a/Å	8.2915(3)		
b/Å	16.8455(6)		
c/Å	10.8081(4)		
α/°	90		
β/°	102.988(4)		
γ/°	90		
Volume/Å ³	1471.00(10)		
Z	4		
ρ _{calc} g/cm ³	1.401		
μ/mm ⁻¹	0.123		
F(000)	656.0		
Crystal size/mm³	$0.42 \times 0.34 \times 0.23$		
Radiation	MoKα (λ = 0.71073)		
2Θ range for data collection/°	4.836 to 61.582		
Index ranges	$-6 \le h \le 11, -23 \le k \le 13, -14 \le l \le 10$		
Reflections collected	6513		
Independent reflections	3917 [R _{int} = 0.0253, R _{sigma} = 0.0453]		
Data/restraints/parameters	3917/0/207		
Goodness-of-fit on F ²	1.031		
Final R indexes [I>=2σ (I)]	$R_1 = 0.0510$, $wR_2 = 0.1142$		
Final R indexes [all data]	$R_1 = 0.0866$, $wR_2 = 0.1368$		
Largest diff. peak/hole / e Å-3	0.22/-0.23		




Figure S7: ORTEP view of compound **5c**^{tt} (**a**) and crystal packing (**b**) showing the thermal ellipsoids at 50% probability (CCDC 2479559).

Table S7: Crystal data and structure refinement for 5ctt			
Empirical formula	C ₁₃ H ₂₁ F ₃ N ₂ O ₃		
Formula weight	310.32		
Temperature/K	295(2)		
Crystal system	monoclinic		
Space group	P2 ₁ /c		
a/Å	8.8586(4)		
b/Å	15.4663(7)		
c/Å	11.8821(5)		
α/°	90		
β/°	104.124(5)		
γ/°	90		
Volume/Å ³	1578.75(13)		
Z	4		
ρ _{calc} g/cm ³	1.306		
µ/mm ⁻¹	0.115		
F(000)	656.0		
Crystal size/mm³	0.46 × 0.19 × 0.06		
Radiation	MoKα (λ = 0.71073)		
2Θ range for data collection/°	4.408 to 62.088		
Index ranges	$-11 \le h \le 12, -21 \le k \le 18, -9 \le l \le 16$		
Reflections collected	7070		
Independent reflections	4287 [R _{int} = 0.0379, R _{sigma} = 0.0762]		
Data/restraints/parameters	4287/0/208		
Goodness-of-fit on F ²	1.005		
Final R indexes [I>=2σ (I)]	$R_1 = 0.0608$, $wR_2 = 0.1332$		
Final R indexes [all data]	$R_1 = 0.1292$, $wR_2 = 0.1711$		
Largest diff. peak/hole / e Å-3	0.24/-0.17		

Table S8: Hydrogen bonds with HA < r(A) + 2.000 Å and <dha> 110°</dha>					
D–H	d(D-H)	d(HA)	<dha< td=""><td>d(DA)</td><td>Α</td></dha<>	d(DA)	Α
4a ^{cc}					
O1–H1	0.85(2)	1.95(2)	169(1)	2.788(2)	N3 [x, 1/2-y, z+1/2]
O2-H2	0.80(2)	1.98(2)	164(1)	2.762(2)	O3 [1-x, 1-y, 1-z]
N3-H3	0.865(15)	2.19(2)	139(1)	2.895(15)	01
4a ^{ct}					
O1-H1	0.86(4)	1.89(4)	173(3)	2.739(5)	O2 [-x-3/2, y, z+1/2]
O3-H3	0.93(6)	1.94(6)	173(4)	2.863(5)	N5 [x-1/2, -y-1, z]
N5-H5	0.77(4)	2.42(4)	129(4)	2.974(5)	01
4a ^{tt}					
O1-H1	0.79(3)	2.00(3)	170(2)	2.782(2)	O3 [x+1/2, y, 3/2-z]
O3-H3	0.88(3)	2.00(3)	168(2)	2.868(2)	O2 [1-x, y-1/2, 3/2-z]
N3-H3A	0.89(2)	2.11(2)	165(1)	2.983(2)	O2 [1-x, y-1/2, +3/2-z]
4a ^{tc}					
O2-H2	0.84(2)	1.86(2)	173(2)	2.693(2)	O1 [1-x, y-1/2, 1/2-z]
O3-H3A	0.84(2)	1.99(2)	166(2)	2.809(2)	O2 [x, y+1, z]
4dct					
N5-H5	0.83(5)	2.39(5)	131(3)	2.998(5)	01
O3-H3A	0.79(5)	1.91(5)	157(4)	2.651(5)	O2A
O1-H1	0.95(5)	1.83(5)	164(3)	2.755(5)	O3A
N5A-H5A	0.91(4)	2.22(4)	132(2)	2.912(4)	O1A
O3A-H3AB	0.83(5)	1.88(5)	169(3)	2.691(5)	O2 [x, -y, z-1/2]
O1A-H1A	0.80(4)	1.84(4)	176(3)	2.638(4)	O3 [x, 1-y, z-1/2]
5ctc					
O3-H3	0.93(3)	1.86(3)	174(2)	2.782(3)	N2 [1-x, y-1/2, 1/2-z]
N2-H2A	0.97(3)	2.18(3)	151(2)	3.064(3)	O1 [1-x, 2-y, 1-z]
N2-H2B	0.90(3)	2.59(3)	149(2)	3.392(3)	O3 [x, 3/2-y, z-1/2]
5c ^{tt}					
N2-H2A	0.88(2)	2.43(2)	138(2)	3.145(2)	F1 [1-x, y+1/2, 1/2-z]
N2-H2B	0.92(2)	2.31(2)	172(2)	3.227(2)	O3 [x, 1/2-y, z-1/2]
O2-H2C	0.93(3)	1.87(3)	174(2)	2.796(2)	N2 [x+1, 1/2-y, z+1/2]

Table S9: Dihedral angles of heterocycles in compounds 4a,d.				
Compound	Pyridone ring	Pyrimidine ring	angles	
4a ^{tt}	C2 C3 C8 C9 C10 N1	C4 C5 C6 N1 C2 N3	24.8(2)	
4a ^{tc}	C6 C7 C8 C9 C10 N1	C2 C3 C4 N5 C6 N1	27.3(3)	
4a ^{cc}	C2 C7 C8 C9 C10 N1	C4 C5 C6 N1 C2 N3	51.5(1)	
4a ^{ct}	C6 C7 C8 C9 C10 N1	C2 C3 C4 N5 C6 N1	49.5(6)	
4d ^{ct}	C6 C7 C8 C9 C10 N1	C2 C3 C4 N5 C6 N1	47.7(7)	
	C6A C7A C8A C9A C10A N1A	C2A C3A C4A N5A C6A N1A	53.9(5)	

Cytotoxicity and anti-viral activity evaluation

Virus and cells. We used MDCK cells (ATCC CCL-34) from the collection of cell lines of the Saint Petersburg Pasteur Institute. Cells were cultured in 96-well culture plates in MEM medium with 10% fetal bovine serum («HyClone», USA), 40 U/ml gentamicin sulfate and 2.5 U/ml amphotericin B. Cell suspension with a concentration of 105 cells/ml was placed in the wells of the plates in volume of 100 μl and cultured until a complete monolayer formation for 24 h at 36 °C in the presence of 5% CO₂. The same medium without serum was used as a support medium for culturing cells with viruses.

We used influenza virus A/Puerto Rico/8/34 (H1N1) from the collection of the Saint Petersburg Pasteur Institute. The infectious titer of virus was determined by titration in 96-well plates with monolayers of MDCK cells. The results were evaluated visually according to the presence of the virus cytopathic action, the virus titer was calculated by the Spearman–Kerber method and represented in decimal logarithms of 50% tissue cytopathic doses in ml (Ig TCD₅₀/ml).

Evaluation of cytotoxic properties of compounds. The assessment of toxicity of compounds was carried out based on evaluation of the cell viability using the reduction reaction of the tetrazolium dye MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2*H*-tetrazolium bromide) by cells in culture. Its intensity shows the degree of cell viability as a result of dye reduction by mitochondrial and partially cytoplasmic dehydrogenases.

The test compounds in the concentration range of $3.7-300~\mu g/ml$ dissolved in the medium for cell cultivation were added to the plate wells in a volume of $200~\mu l$ and incubated for 48~h at $36~^{\circ}C$ in atmosphere of $5\%~CO_2$. At the end of the incubation period, the cells were washed with MEM medium, and $100~\mu l$ of a solution (0.5~mg/ml) of MTT in the cell medium was added to the plate wells. The cells were incubated at $36~^{\circ}C$ at $5\%~CO_2$ for 2~h and washed for 5~min with saline. The precipitate was dissolved in $100~\mu l$ of DMSO per well, and the optical density was measured using a Multiscan FC plate analyzer (Thermo Scientific) at a wavelength of 540~nm. Based on the obtained data, the 50%~cytotoxic concentration (CC_{50}) was calculated, i.e., the concentration of the compound, which reduces the optical density in the wells by half compared to control cells without drugs. For this purpose, GraphPad Prism 6.01~software was used.

Evaluation of anti-viral activity of compounds. The compounds in appropriate concentrations were added to MDCK cells (0.1 ml per well). After 1 h of incubation, cells were infected with influenza virus A/Puerto Rico/8/34 (H1N1) (moi 0.01) and incubated

for 48 h at 36 °C and 5% CO₂. After that, cell viability was assessed by MTT test as described above. The cytoprotective activity of compounds was considered as their ability to increase the values of OD comparing to control wells (with virus only, no drugs). Based on the results obtained, the values of IC₅₀, i.e., concentration of compounds that result in 50% cells protection were calculated using GraphPad Prism 6.01 software. Values of IC₅₀ obtained in μ g/ml were then calculated into micromoles (μ M). For each compound the value of selectivity index (SI) was calculated as ratio of CC₅₀ to IC₅₀. Compounds with SI of 10 and higher were considered active. Ribavirin was used as a reference compound.

References

- [1] Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. *J. Appl. Crystallogr.* **2009**, *42*, 339–341. doi:10.1107/S0021889808042726
- [2] Sheldrick, G. M. *Acta Crystallogr. C: Struct. Chem.* **2015**, *C71*, 3–8. doi:10.1107/S2053229614024218
- [3] Sheldrick, G. M. *Acta Crystallogr. A: Found. Adv.* **2015**, *A71*, 3–8. doi:10.1107/S2053273314026370

Copies of ¹H, ¹⁹F and ¹³C NMR spectra




Figure S8: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 4a^{cc}.




Figure S9: 13 C NMR (126 MHz, DMSO- d_6) spectrum of $4a^{cc}$.




Figure S10: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of **4a**^{cc}.




Figure S11: ¹H NMR (400 MHz, DMSO-d₆) spectrum of **4a**^{ct}.




Figure S12: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4a^{ct}.





Figure S13: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4a^{ct}.



180 170 160 150 140 130 120 110 100 90 Figure S15: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4a^{tt}.

80

70




Figure S16: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4att.




Figure S17: ¹H NMR (400 MHz, DMSO-d₆) spectrum of **4a**^{tc}.




Figure S18: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4a^{tc}.




Figure S19: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4a^{tc}.





Figure S21: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4b^{ct}.






Figure S23: ¹H NMR (500 MHz, DMSO-*d*₆) spectrum of a mixture of diastereomers **4b**^{cc} and **4b**^{tc}.




Figure S24: ¹³C NMR (126 MHz, DMSO- d_6) spectrum of a mixture of diastereomers **4b**^{cc} and **4b**^{tc}.




Figure S25: ¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum of a mixture of diastereomers **4b**^{cc} and **4b**^{tc}.




Figure S26: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 4c^{cc}.




Figure S27: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4c^{cc}.




Figure S28: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4c^{cc}.




Figure S29: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 4c^{ct}.




Figure S30: 13 C NMR (126 MHz, DMSO- d_6) spectrum of $4c^{ct}$.




Figure S31: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4cct.




Figure S32: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 4d^{cc}.




Figure S33: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4d^{cc}.




Figure S34: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4dcc.




Figure S35: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 4d^{ct}.




Figure S36: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 4d^{ct}.




Figure S37: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 4dct.




Figure S38: ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of a mixture of diastereomers **5a**^{tc} and **5a**^{tt}.




Figure S39: 13 C NMR (126 MHz, DMSO- d_6) spectrum of a mixture of diastereomers ${\bf 5a^{tc}}$ and ${\bf 5a^{tt}}$.




Figure S40: ¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum of a mixture of diastereomers **5a**^{tc} and **5a**^{tt}.




Figure S41: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 5b^{tc}.




Figure S42: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 5b^{tc}.




Figure S43: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 5b^{tc}.




Figure S44: ¹H NMR (500 MHz, DMSO-d₆) spectrum of **5b**^{tt}.




Figure S45: 13 C NMR (126 MHz, DMSO- d_6) spectrum of 5btt.




Figure S46: ¹⁹F NMR (470 MHz, DMSO-*d*₆) spectrum of **5b**^{tt}.






Figure S47: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 5ctc.





Figure S48: 13 C NMR (126 MHz, DMSO- d_6) spectrum of $5c^{tc}$.






Figure S49: ¹⁹F NMR (376 MHz, DMSO-d₆) spectrum of 5ctc.




Figure S50: ¹H NMR (400 MHz, DMSO-d₆) spectrum of 5ctt.




Figure S51: ¹³C NMR (126 MHz, DMSO-d₆) spectrum of 5ctt.




Figure S52: ¹⁹F NMR (376 MHz, DMSO- d_6) spectrum of 5c^{tt}. Copies of IR spectra

25.12.2023 100-99 2969 2872 2767 96-94-Отражение 93-92-91-90-89-88-HO, 87-86-HO Me 3000 2000 1500 1000 500

Figure \$53: IR spectrum of 4acc.

Волновое число (см-1)




Figure S54: IR spectrum of 4act.




Figure S55: IR spectrum of 4att.




Figure S56: IR spectrum of 4atc.




Figure S57: IR spectrum of 4bct.




Figure S58: IR spectrum of a mixture of diastereomers 4bcc and 4btc.




Figure S59: IR spectrum of 4ccc.




Figure S60: IR spectrum of 4cct.




Figure S61: IR spectrum of 4dcc.




Figure S62: IR spectrum of 4dct.




Figure S63: IR spectrum of a mixture of diastereomers $\mathbf{5a^{tc}}$ and $\mathbf{5a^{tt}}$.




Figure S64: IR spectrum of 5btc.




Figure S65: IR spectrum of 5btt.




Figure S66: IR spectrum of 5ctc.




Figure S67: IR spectrum of 5ctt.

Copies of HRMS spectra






Figure S68: HRMS (ESI) spectrum of 4acc.

Cmpd 1, 1.1 min




Figure S69: HRMS (ESI) spectrum of 4act.

Cmpd 1, 0.8 min




Figure \$70: HRMS (ESI) spectrum of 4att.






Figure S71: HRMS (ESI) spectrum of 4atc.

Cmpd 1, 0.7 min




Figure S72: HRMS (ESI) spectrum of 4bct.






Figure S73: HRMS (ESI) spectrum of a mixture of diastereomers 4bcc and 4btc.






Figure S74: HRMS (ESI) spectrum of 4ccc.

Cmpd 1, 0.7 min




Figure S75: HRMS (ESI) spectrum of 4cct.

Cmpd 1, 0.6 min




Figure S76: HRMS (ESI) spectrum of 4dcc.






Figure S77: HRMS (ESI) spectrum of 4dct.

Cmpd 2, 2.1 min




Figure S78: HRMS (ESI) spectrum of mixture of diastereomers 5atc and 5att.

Cmpd 1, 1.4 min




Figure S79: HRMS (ESI) spectrum of 5btc.

Cmpd 1, 1.1 min




Figure S80: HRMS (ESI) spectrum of 5btt.






Figure S81: HRMS (ESI) spectrum of 5ctc.

Cmpd 1, 2.0 min




Figure S82: HRMS (ESI) spectrum of 5ctt.